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ABSTRACT  39 
Introduction 40 
Fever is a frequent reason of consultation in children, but correctly identifying the few febrile children 41 
with potentially severe bacterial infections is difficult. This encourages clinicians to prescribe empirical 42 
antibiotics and subject children to extensive and sometimes invasive testing. Rapid point of care tests 43 
(POCTs) are recommended internationally to reduce the use of antibiotics and medical resources. The 44 
extent of the availability and use of POCTs by paediatricians in Europe is unclear, but appears to vary 45 
widely across countries. The aim of this study is to document the availability and use of rapid POCTs 46 
for the clinical management of acute childhood infections and to identify factors associated with the 47 
variability of their adoption across Europe. 48 
Methods and analysis 49 
The study is an online cross-sectional survey of paediatricians working in primary care and hospitals 50 
in more than 24 European countries. Participants were recruited through several European research 51 
and clinical networks  52 
Descriptive statistics will be used to describe the availability of rapid POCTs to paediatricians and the 53 
use of rapid POCTs in a clinical scenario of an infant with undifferentiated fever. Weighted regression 54 
analyses will identify factors of the availability and use of rapid POCTs across the included countries. 55 
Ethics and dissemination  56 
Participating to this anonymous survey does not carry any risk. Ethical approval was obtained from 57 
the London School of Hygiene and Tropical Medicine Ethics Committee. 58 
The results of the survey will be presented at European paediatrics conferences and submitted for 59 
publication in peer-reviewed medical journals. This study will contribute to understanding the reasons 60 
for the variability in the adoption of rapid POCTs across different countries. The findings from this 61 
study will be useful for clinicians, health services and the industry developing and implementing rapid 62 
POCTs, particularly for the clinical management of febrile children. 63 
Key words  64 
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ARTICLE SUMMARY 66 
Strengths and limitations of this study  67 
 Paediatricians from 24 European countries were recruited through several pan-European 68 
research networks and national professional associations of general, infectious diseases, and 69 
emergency medicine paediatricians working at primary care and hospital levels 70 
 The survey materials were developed through a robust process including the involvement of 71 
experts from 10 European countries, two pilot pre-studies, the translation of the 72 
questionnaires into 10 languages, and the use of a software which allowed several quality 73 
assurance checks, such as mandatory questions, adaptative questions, consistency and 74 
completeness checks, and the prevention of automated multiple entries 75 
 The main limitation is the non-probabilistic nature of the sampling approach, which implies 76 
that there may have been selection bias 77 
 Response rates may be low, given the online nature of the survey, and there is a risk of 78 
response fatigue, given the number of questions, which may have led to non-response bias 79 
and loss of statistical power 80 
 We used one specific clinical scenario to explore the use of rapid POCTs, which implies that 81 
the findings of the study will not necessarily be generalisable to other clinical scenarios 82 
 83 
 84 
 85 
 86 
 87 
 88 
 89 
 90 
 91 
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INTRODUCTION 92 
Fever is a frequent cause of consultation in children.1 On average, children under five years of age 93 
experience two episodes of fever annually.2,3 Most febrile children have an infection. Infections cause 94 
32% of under-five deaths globally.4 However, most infections in children are self-limiting.5-7 Severe 95 
bacterial infections represent less than 1% of febrile children consulting in primary care,5 and 7-15% 96 
of those presenting to emergency departments.6,7  97 
Correctly identifying the few children with potentially severe bacterial infections is difficult.5 At 98 
primary care level, clinicians have limited access to diagnostics and use their clinical expertise. 99 
However, history and physical examination may be unspecific.5 As a result, antibiotics are often 100 
prescribed to ensure no potentially severe bacterial infections are left untreated.8 On the other hand, 101 
some children who are developing an invasive bacterial infection may be sent home without 102 
treatment because they lack specific symptoms at the time of consultation. 103 
At hospital level, clinicians often admit young febrile children to rule-out potentially severe infections. 104 
During the hospitalisation, children are monitored, and undergo several, sometimes invasive, 105 
diagnostic tests. It can take 48 hours or more for some of the tests such as blood cultures to return 106 
results. In the meantime, children receive broad-spectrum antibiotics, while most of them actually do 107 
not have a severe bacterial infection.6,7 This approach can result in anxiety and discomfort for children 108 
and their parents, expensive hospitalisations,9 and may contribute to the development of 109 
antimicrobial resistance (AMR).10 110 
The World Health Organization recommends using rapid point-of-care tests (POCTs) to reduce 111 
antibiotic prescription because they can be easily performed and provide rapid results to aid clinical 112 
decision-making.11 The use of rapid POCTs could also limit the use of other invasive tests, and allow a 113 
better use of medical resources.12 There are three main types of rapid POCTs for the management of 114 
acute infections in children. The first are tests that detect the presence of a specific pathogen, such as 115 
group A Streptococci (GAS), or influenza.13,14 The second type are tests that measure the host reaction 116 
to infection, such as tests measuring C-reactive protein (CRP), or procalcitonin (PCT).15 These latter 117 
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tests are useful in febrile children with no other clinical signs to rule-in or out bacterial infections16 118 
and as an indicator of severity, even if the pathogen and/or the location of infection is not identified. 119 
The third type are tests that detect both the pathogens and the host reaction, for example urine 120 
dipsticks, which can indicate the presence of nitrites produced by bacteria, and of leucocyte esterase, 121 
an enzyme produced by the hosts during bacterial infections.17  122 
The impact of rapid POCTs depends on several factors, including their analytical and clinical 123 
performance, but also their adoption by clincians.18 For example, effective rapid POCTs to diagnose 124 
malaria are available. However, many clinicians in malaria-endemic countries prescribe antimalarials 125 
even when patients test negative, because they are reluctant to shift from reliance on clinician 126 
judgement, or mistrust test results.19  127 
There seems to be a wide variability in the availability and use of rapid POCTs across Europe.  However, 128 
evidence describing the availability and use is scarce and mainly limited to studies on the use of POCTs 129 
by General Practitioners (GPs) in adults in northern countries.  These show that tests POCTs to detect 130 
GAS are widely used in France20 and CRP POCTs are used in almost all GP practices in Sweden21-25 and 131 
Denmark,26 while the proportion of GPs which use the test is 3% in Belgium, 15% in the United 132 
Kingdom, and 48% of in the Netherlands.27 Urine dipsticks seem to be widely used across Europe.27-29  133 
The availability and use of rapid POCTs in the management of febrile children across Europe is unclear, 134 
but also appears to vary. This variability could be explained by health systems and policy factors while 135 
the variability in the use of the tests could be due to characteristics of clinicians, such as specialization, 136 
or years of experience, and their attitudes towards rapid POCTs. 137 
The aim of this study is to document the variability in the availability and use of rapid POCTs for the 138 
clinical management of acute childhood infections in Europe and to identify factors associated with 139 
the variability. The knowledge generated by the study will inform the development and 140 
implementation of current and future rapid POCTs in different European countries. 141 
METHODS AND ANALYSIS 142 
6 
 
The study is an online cross-sectional survey of paediatricians working in primary care and in hospitals 143 
in Europe. Data collection was conducted between September and November 2019.  144 
Outcomes 145 
1. Primary outcomes: 146 
I. Proportion of participants who report the availability of CRP POCT in their workplace.  147 
CRP was chosen because it is one of the most widely used and researched non-specific 148 
tests for indicating bacterial infection and severity, and is a blood test (as are many of 149 
the new tests in development) 150 
II. In those reporting that CRP POCT is available in their workplace, the proportion of 151 
participants who report they would use it in a clinical scenario (i.e. a febrile infant with 152 
no clear focus)  153 
2. Secondary outcomes include: 154 
I. Proportion of participants who would like specific rapid POCTs to be made available  155 
II. Proportion of participants who report the availability of other rapid POCTs (e.g. urine 156 
dipsticks) in their main workplace.  157 
III. Proportion of participants who report the use of diagnostic tests other than CRP POCT 158 
in the clinical scenario. Proportion of participants reporting different reasons for using 159 
diagnostic tests in the clinical scenario. Characteristics of future rapid POCTS for the 160 
management of acute childhood infections considered to be most important by 161 
participants. 162 
Study setting 163 
We aim to include clinicians providing healthcare to acutely ill children from any European country. 164 
The authors are members of several European paediatric research networks (see below) which 165 
between them have a strong presence in 24 countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, 166 
Finland, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Malta, the Netherlands, 167 
Norway, Poland, Portugal, Slovenia, Spain, Switzerland, Ukraine, and the United Kingdom. We expect 168 
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that most participants will be from these targeted countries. These countries represent a wide 169 
spectrum of European countries in terms of potentially important characteristics, including who 170 
delivers most primary healthcare to children (paediatricians or GPs), and the financing mechanisms 171 
for health services.  172 
Recruitment of participants  173 
To be included, participants needed to fulfil the following criteria: 174 
 Be a clinically active paediatrician providing acute care to children based either in primary 175 
care or in hospital 176 
 Be a general paediatrician or paediatrician with a subspecialty or special interest 177 
(particularly in infectious diseases and emergency medicine) 178 
We included both junior doctors and consultants, and doctors working in either the private or public 179 
sector in any European country. Paediatricians not clinically active or medical students were not 180 
included.  181 
Participants were identified through the following networks: 182 
 Personalised Risk assessment in febrile illness to optimise Real-life Management across the 183 
European Union (PERFORM) network, a European research consortium which aims to improve 184 
the clinical management of febrile children30 185 
 European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet)31   186 
 European Society of Paediatric Infectious Diseases (ESPID)32 187 
 Research in European Paediatric Emergency Medicine (REPEM)33 188 
 National associations of paediatrics, paediatric infectious diseases, and paediatric emergency 189 
medicine from the countries listed above (Additional file 1) 190 
Within each network, an authorised person emailed an invitation to all members, using internal email 191 
lists, except in the UK where the invitation was incorporated in the newsletter of the national 192 
association (Royal College of Paediatrics and Child Health). Three reminders were sent two weeks 193 
apart. Participation was monitored weekly, and in countries with low participation, national 194 
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coordinators, who were members of one of the above networks, further disseminated the survey 195 
locally through professional networks, or during conferences or workshops. In the UK, the survey was 196 
also disseminated by the national association’s social media account.  No incentives were offered to 197 
potential participants.  198 
Sample size  199 
The sample size was computed to allow estimation of the two main outcomes of interest (the 200 
availability of CRP POCT, and the use of CRP POCT in the clinical scenario) with a certain degree of 201 
precision (Table 1). We considered primary care and hospital paediatricians as two different 202 
populations because of the differences in the availability of diagnostics and the overall context of care 203 
in those settings, as well as different a priori chance of bacterial infection in children in these settings.  204 
We assessed whether these sample sizes would also allow identification of determinants of the main 205 
outcomes of interest with sufficient statistical power in multiple logistic regression analyses. Based on 206 
a rule of thumb  of doubling the sample size to allow for multivariable analyses, we considered that if 207 
half of the sample sizes in Table 1 would allow detection of a difference in the main outcomes of 208 
interest between categories of the main hypothesised explanatory variables (health expenditure per 209 
capita for CRP POCT availability, and years of clinical experience for CRP POCT use), with >90% power, 210 
then the full samples sizes presented in Table 1 would also be sufficient for the regression analyses. 211 
With regards the determinants of CRP POCT availability, we grouped countries into two categories of 212 
health expenditure per capita (HEC): category 1 grouped countries spending ≤2,800 Euros per capita 213 
and category 2 countries spending >2,800 Euros, as 2,800 Euros is the median HEC of the countries 214 
included in the study34,35 (Table 2). We hypothesised that CRP POCT would be available to 50% of 215 
clinicians in the >2,800 Euros group based on the availability of CRP POCT in the Netherlands,27 216 
compared to 25% in the ≤2,800 Euros. The power to detect a difference between the two groups (with 217 
252 primary care paediatricians in the ≤2,800 Euros category versus 241 in the >2,800 category, and 218 
322 hospital paediatricians in the ≤2,800 Euros category versus 385 in the >2,800category, Table 2) 219 
would be 100% in both primary care and hospital settings. With regards the determinants of CRP POCT 220 
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use in the clinical scenario, we grouped participants into two categories: category 1 grouped 221 
participants with ≤ 10 years of experience, category 2 participants with >10 years of experience.36 We 222 
considered that 20% of the sample will have ≤10 years of experience, based on European figures of 223 
years of experience of medical doctors.37 We hypothesised that less experienced paediatricians would 224 
use CRP POCT in 45% of patients in the clinical scenario, while more experienced paediatricians will 225 
do so in 25% of patients, based on the median rate of CRP use in febrile infants from 11 European 226 
hospitals members of the PERFORM consortium (unpublished data). The power to detect a difference 227 
between the two groups (with 99 primary care paediatricians in the ≤10 years of experience category 228 
versus 394 in the >10 years of experience category, and 141 hospital paediatricians in the ≤10 years 229 
of experience category versus 566 in the >10 years of experience category, Table 3) would be 97% in 230 
primary care and 99% in hospital settings. Thus, the sample sizes in table 1 would ensure that the 231 
planned regression analyses have sufficient power.  232 
Consent and confidentiality 233 
The invitation email provided information about the identity of the research team, the aim and nature 234 
of the study, the reason for contacting the recipient, and the time needed to complete the 235 
questionnaire (approximately 10 minutes). The email included a weblink to access the online survey. 236 
The first page of the survey consisted of a participant information sheet which further informed 237 
participants about the anonymous nature of the survey, the storing of all data for 10 years in the 238 
London School of Hygiene and Tropical Medicine (LSHTM) secure data server, which is password 239 
protected and only accessible to Juan Emmanuel Dewez (JED) and Shunmay Yeung (SY). The page also 240 
contained a consent box that participants had to tick to confirm they agree to take part to the study 241 
and to access the website hosting the questionnaires. 242 
Data collection tools 243 
Data were collected through an on-line structured questionnaire.  There were two questionnaires: 244 
one targeting primary care paediatricians and another for hospital paediatricians.  Most questions 245 
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were identical in the two questionnaires (14 questions were different). The questionnaires were 246 
developed based on a literature review and had four sections (Additional file 2): 247 
1. Section A: general characteristics of participants and their workplace 248 
2. Section B: availability of rapid POCTs in the workplace 249 
3. Section C: clinical scenario and use of diagnostics in the scenario 250 
4. Section D: characteristics of future diagnostics that are important to participants 251 
The actual number of questions varied from 43 to 58 questions, depending on how the respondent 252 
answered certain questions (i.e. selecting specific answers to some questions gave access to 253 
additional questions). Collaborators from the targeted countries tested the initial drafts and provided 254 
input to improve the relevance of the questionnaires for their countries. The questionnaires were 255 
piloted for the first time during the paediatric infectious diseases master course of the 2017 European 256 
Academy of Paediatrics annual conference with 58 attendees, and adapted after analysis to improve 257 
the clarity and relevance of questions. The survey was developed in English and translated into 258 
French, German, Greek, Hungarian, Italian, Latvian, Polish, Spanish, Slovenian, and Ukrainian by a 259 
bilingual translator. This was followed by a back translation into English by another bilingual translator 260 
blinded to the original version. Any disagreement was solved through discussion with collaborators 261 
from the respective countries. There were a few exceptions with no back translation: the translations 262 
into French and Spanish were made by JED, who was one of the main developers of the 263 
questionnaires, and checked for accuracy by collaborators from France and Spain; the Slovenian 264 
translation was made by a Slovenian collaborator and checked by two other collaborators without 265 
back translation. Collaborators from each country checked the final online versions and provided 266 
feedback to correct typographical and formatting errors. The final version was piloted in Norway and 267 
Slovenia in June-July 2019 with 115 participants who could provide feedback by email. No technical 268 
issues were reported during the pilot. A few typographical errors were corrected after the second 269 
pilot.  270 
Software and data management  271 
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We used software developed by a professional company with a track record in conducting online 272 
surveys.39-41 Questions were mandatory except three questions. Most questions were closed-273 
questions with a single answer from a drop-down menu; six questions were open with free text 274 
answers. The order of questions was not randomised. Questions were displayed in 13 pages. Pages 275 
contained between 1 to 10 questions. Completeness of each page and accuracy of responses (e.g. 276 
some of the free text answers had to be numerical answers) was checked through JAVAscripts. 277 
Participants were able to return to previous questions and change their answers. Data were 278 
automatically saved into a database after completion of each page. There was no technical means to 279 
prevent multiple entries by the same participant. A challenge-response test (CAPTCHA) was 280 
mandatory at the beginning of the questionnaire to prevent automated multiple entries by a 281 
computer.  282 
Analysis 283 
Only complete questionnaires will be analysed. Questionnaires that were completed in less than two 284 
minutes will be excluded, as completing the questionnaire in less than two minutes is possible only if 285 
respondents do not fully engage with the questions and provide random answers.  286 
There might be response bias related to characteristics of participants (e.g. there might be more 287 
younger respondents because of the online nature of the survey, or more participants with a special 288 
interest in, for example, infectious diseases). To address this, we will use non-response weighting42 to 289 
weight the data to replicate the distribution of the different sub-groups (including age groups, 290 
subspecialty groups) in the total population of paediatricians per country, provided that auxiliary data 291 
on these characteristics are available. Moreover, there will be an over-representation of participants 292 
from smaller countries given that the sample sizes are similar while the total population of 293 
paediatricians per country vary widely (Table 1). To address this in the analyses that use combined 294 
data from several countries (e.g. means across group of countries) we will use population size 295 
weighting.42 The population size weight will be combined with the non-response weight.  296 
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Descriptive statistics will be used to derive the proportions of participants with relevant characteristics 297 
(including country of work, years of practice, type of workplace, subspecialty, etc), response rates per 298 
research network, availability of rapid POCTs, use of diagnostic tests in the clinical scenario, proportion 299 
of participants who agree/disagree with reasons to use tests, and future characteristics (including 300 
purposes of new tests, time to get results). 301 
Multiple logistic regression analyses will be performed to identify determinants of CRP POCT 302 
availability, and CRP POCT use in the clinical scenario for each level of care (primary care and hospital 303 
care). Expected explanatory variables are presented in table 4. Univariable analysis of the explanatory 304 
variable against the outcomes of interest will be performed initially to develop the model. 305 
Multicollinearity will be assessed to drop one of the pair of correlated variables. Data from 306 
questionnaires with missing independent variables or the outcome variables will not be used in the 307 
model. Given that all the hypothesised explanatory variables were identified through a review of the 308 
literature, they will all be included in the model a priori (except those that are highly correlated).,  309 
All analyses will be performed with Stata 16.®  310 
Patient and Public Involvement 311 
Patients and the public were not involved in the development of this protocol.  312 
ETHICS AND DISSEMINATION 313 
Participating to the survey does not carry any substantial risk. Paediatricians may feel that the research 314 
team is making judgements or evaluating the provision of care. To mitigate against this, it was clearly 315 
explained during the consent process that the aim of the study was not to assess the quality of care 316 
but to describe and understand the use of POCTs in the participants’ workplaces. The inconvenience 317 
for participants of taking time away from work might be a minimal source of discomfort as the survey 318 
completion takes only about 10 minutes. All participants provided electronic written informed 319 
consent. Ethical approval was obtained from the LSHTM Ethics Committee (Ref: 15977). 320 
The results of the survey will be presented at European conferences of paediatrics (ESPID and EAP) 321 
and submitted for publication in peer-reviewed medical journals. The results will also be presented at 322 
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the final meeting of the PERFORM consortium, which gathers stakeholders in the field of the 323 
management of acute childhood infections from across Europe. The datasets generated during the 324 
current study will not publicly available but will be available from the corresponding author on 325 
reasonable request. 326 
DISCUSSION  327 
This study will contribute to understanding the reasons for the variability in the adoption of rapid 328 
POCTs, the use of which is recommended internationally to improve the use of antibiotics and medical 329 
resources in general. The findings from this study will be useful for clinicians, health services and the 330 
industry currently developing or implementing rapid POCTs, particularly for the clinical management 331 
of febrile children. The identification of countries where rapid POCTs have been adopted will also 332 
inform the development of additional in-depth studies in those countries to learn more about the 333 
contexts, actors, and processes which led to the successful implementation of rapid POCTs in clinical 334 
practice. 335 
Strengths  336 
This is a survey of paediatricians from across Europe.  We used several pan-European research 337 
networks and national professional associations of general, infectious diseases, and emergency 338 
medicine paediatricians working at primary care and hospital levels to reach out to a broad range of 339 
paediatricians in 24 countries.  In our analytical approach we will use available data to attempt to 340 
estimate how representative our sample is of paediatricians in those countries, and we will also be 341 
specifically exploring the contribution of health system factors in influencing the availability of 342 
diagnostic tests.  343 
The survey materials were developed through a robust process including the involvement of experts 344 
from 10 European countries, two pilot pre-studies, the translation of the questionnaires into 10 345 
languages, and the use of a software which allowed several quality assurance checks, such as 346 
mandatory questions, adaptative questions, consistency and completeness checks, and the 347 
prevention of automated multiple entries.  348 
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Limitations  349 
The main limitation is the non-probabilistic nature of the sampling approach, which implies that there 350 
may have been selection bias. Obtaining comprehensive sampling frames from each country to select 351 
participants randomly would have required a much greater level of engagement with local health 352 
authorities, which was not possible. 353 
Response rates may be low, given the online nature of the survey,43 and there is a risk of response 354 
fatigue, given the number of questions, which may have led to non-response bias and loss of statistical 355 
power. Other risks of bias common in surveys, including social desirability, hypothesis guessing, and 356 
cultural bias,44 are also possible. 357 
We used one specific clinical scenario to explore the use of rapid POCTs, which implies that the findings 358 
of the study will not necessarily be generalisable to other clinical scenarios.  359 
Finally, GPs are also an important provider of healthcare to children in some countries. We did not 360 
approach GPs, because this would have required substantial additional resources.  361 
Word count: 3,974  362 
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TABLES 521 
Table 1. Sample sizes to estimate the main outcomes (current availability of CRP POCT, and use 
of CRP POCT in a clinical scenario) with 90% confidence, a margin of error below 10%, and an 
expected proportion of the outcomes of 50% 
Country   Total population of 
primary care 
paediatricians37,38*  
Sample size of 
primary care 
paediatricians  
Total population of 
hospital 
paediatricians37,38*  
Sample size of 
hospital 
paediatricians  
Austria 585 61 774 62 
Belgium 782 65 781 65 
Bulgaria NA NA 1,475 65 
Croatia 281 55 583 61 
Cyprus 180 49 68 34 
Finland 73 35 623 61 
France 1,453 65 6,622 67 
Germany 5,991 67 7,924 67 
Greece 2,128 65 2,130 65 
Hungary 939 63 1,432 65 
Israel 501 60 1,699 65 
Italy 6,000 67 11,354 67 
Latvia 10 9 238 53 
Lithuania 40 25 676 61 
Malta NA NA 81 37 
Netherlands NA NA 1,751 65 
Norway NA NA 875 63 
Poland 5,040 67 9,905 67 
Portugal NA NA 2,085 66 
Slovenia 252 53 396 58 
Spain 4,800 67 7,589 67 
Switzerland 978 63 839 63 
Ukraine 3,321 66 6,236 67 
United 
Kingdom 
NA NA 10,464 67 
TOTAL 17,514 1,002 76,600 1,478 
NA: not applicable  
*Except for Spain and Poland, where figures were not available and provided by local partners   
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Table 2. Expected number of participants and health expenditure per capita categories  
Country 
 
Health expenditure 
per capita per year 
category (Euros)34,35 
Half of primary care 
paediatricians’ sample 
size  
Half of hospital 
paediatricians’ sample 
size 
Bulgaria 
≤2,800 
NA 32 
Croatia  27 30 
Cyprus 24 17 
Greece 32 32 
Hungary 31 32 
Israel 30 32 
Latvia 4 36 
Lithuania 12 30 
Malta  NA 18 
Poland 33 33 
Slovenia 26 29 
Ukraine  33 33 
Sub total  252 322 
Austria 
>2,800 
30 31 
Belgium 32 32 
Finland  17 30 
France 32 33 
Germany 33 33 
Italy 33 33 
Netherlands NA 32 
Norway NA 31 
Portugal NA 33 
Spain 33 33 
Switzerland 31 31 
United Kingdom NA 33 
Subtotal  241 385 
TOTAL 
 
 
493 707 
NA: not applicable    
    
Table 3. Expected number of participants and years of clinical experience   
Years of clinical experience  Half of primary care 
paediatricians’ sample size (all 
countries) 
Half of hospital 
paediatricians’ sample size 
(all countries) 
Any experience  493 707 
<10 years of practice (20% of 
any experience)37 
99 141 
>10 years of practice (80% of 
any experience)37 
394 566 
 522 
 523 
 524 
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 525 
Table 4. Explanatory variables for the logistic regression analyses 
A priori explanatory variables of CRP POCT availability in primary care practices 
1.      Country reimbursement mechanisms for diagnostics 
2.    Country level of health expenditure per capita  
3.    Main type of healthcare worker in charge of providing primary care to children (e.g. 
Paediatrician or   general practitioner) 
4.      Sector of activity (public or private) 
5.      Distance between workplace and the nearest external laboratory  
6.    Type of practice (solo or group practice) 
7.      Main type of healthcare worker in charge of taking bloods in children (e.g. doctor or nurse) 
8.    Turnaround time to get results of blood tests such as C-reactive protein or full blood count  
A priori explanatory variables of CRP POCT availability in hospitals 
1.      Country reimbursement mechanisms for diagnostics 
2.    Country level of health expenditure per capita  
3.    Type of hospital (e.g. paediatric or general hospital) 
4.    Level of care (secondary or tertiary level of care) 
5.      Sector of activity (public or private) 
6.      Main type of healthcare worker in charge of taking bloods in children (e.g. phlebotomist, lab 
technician, doctor or nurse) 
7.    Turnaround time to get results of blood tests such as C-reactive protein or full blood count  
A priori explanatory variables for determinants of CRP POCT use by primary care paediatricians 
1.       Years of practice since graduation from medical school 
2.       Sector of activity (public or private) 
3.       Distance between workplace and the nearest external laboratory  
4.     Type of practice (solo or group practice) 
5.       Main type of healthcare worker in charge of taking bloods in children (e.g. doctor or nurse) 
6.     Turnaround time to get results of blood tests such as C-reactive protein or full blood count  
7.       Duration of consultations in busiest weeks of the year 
8.     Current availability of CRP POCT 
9.       Participant’s perceived prevalence of bacterial infection in the clinical scenario  
A priori explanatory variables for determinants of CRP POCT use by hospital paediatricians 
1.      Subspecialisation or special interest of doctors 
2.      Type of hospital (e.g. paediatric or general hospital) 
3.      Level of care (secondary or tertiary level of care) 
4.      Hospital department where participant mainly work 
5.      Years of practice since graduation from medical school 
6.      Sector of activity (public or private) 
7.      Main type of healthcare worker in charge of taking bloods in children (e.g. phlebotomist, lab 
technician, doctor or nurse) 
8.      Turnaround time to get results of blood tests such as C-reactive protein or full blood count  
9.      Duration of consultations in busiest weeks of the year 
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10.    Participant’s perceived prevalence of bacterial infection in the clinical scenario 
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